Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy

European Journal of Medical Research

Volumn 11, Issue 10, 2006, Pages 423-431

  Faber, Lothar ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

HCM; HNCM; HOCM; Hypertrophic obstructive cardiomyopathy; Myectomy; Percutaneous septal ablation; Risk stratification

Indexed keywords

ALCOHOL; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; INOTROPIC AGENT; SHU 508; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; BALLOON CATHETER; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BYPASS GRAFT; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; GENE MUTATION; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VALVE REPLACEMENT; HEART VENTRICLE SEPTUM; HEART VENTRICLE SEPTUM RUPTURE; HEREDITY; HISTOPATHOLOGY; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERMETHOD COMPARISON; INTERNATIONAL CLASSIFICATION OF DISEASES; MORTALITY; MUSCLE RESECTION; MYOTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE PERIOD; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE;

CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ETHANOL; HEART SEPTUM; HUMANS; PATIENT SELECTION;

EID: 33751072901     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. ACC/ESC Clinical Expert Consensus Document on HCM. Eur. Heart J. 2003; 24: 1965-91
2. Braunwald E: Induced septal infarction: A new strategy for hypertrophic obstructive cardiomyopathy. Circulation 1997; 95: 1981
3. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 2001; 38: 846-53.
4. Chang, SM, Lakkis NM, Franklin J, Spencer WHIII, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004; 109: 824-827
5. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat M, Varnava A, Mahon NG, McKenna WJ. Sudden death in HCM: Identification of high.risk patients. J. Am. Coll. Cardiol. 2000; 36: 2212-8
6. Faber L, Seggewiss H, Gleichmann U: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intra-procedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-21
7. Faber L, Seggewiss H, Ziemssen P: Targeting percutaneous transluminal septal ablation for HOCM by intra-procedural echocardiographic monitoring. J. Am. Soc. Echocardiogr. 2000; 13: 1074-9.
8. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D. Vorhersage des Risikos permanenter atrioventrikulärer Überleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie. Z. Kardiol 2003; 92: 39-45
9. Faber L, Meissner A, Ziemssen P, Seggewiss H: Percutaneous transluminal septal myocardial ablation for HOCM: Long-term follow-up in the first series of 25 patients. Heart 2000; 83: 326-31.
10. Flores-Ramirez R; Lakkis NM; Middleton KJ; Killip D; Spencer WH 3rd; Nagueh SF: Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 2001; 37: 208-14.
11. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn H: Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur. Heart J. 1999; 20: 1342-54.
12. Heric B, Lytle BW, Miller OP. Surgical management of hypertrophic obstructive cardiomyopathy. J. Thor. Cardiovasc. Surg. 1995; 110: 195-208
13. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004; 109: 452-6.
14. Knight CJ, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U: Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997; 95: 2075-81
15. Kuhn H, Gietzen F, Leuner C, Gerenkamp T: Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur. Heart J. 1997; 18: 846-51
16. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L. Catheter-based therapy for hypertrophic obstructive cardiomyopathy: First in-hospital outcome analysis of the German TASH Registry. Z Kardiol. 2004; 93: 23-31.
17. Lakkis NM, Nagueh SF; Kleiman NS, Killip DM, He ZX, Verani M, Roberts R, Spencer WH III: Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-5.
18. Maron BJ, Nishimure RA, McKenna WJ et al. Assessment of permanent dual-chamber pacing as treatment for drug refractory patients with obstructive HCM (M-PATHY). Circulation 1999; 99: 2927-33
19. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'Rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL Jr, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oro A, Parkhomenko A, Silber S, Torbicki A. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2003; 42: 1687-713.
20. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik JA, Spencer WH. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 2001; 38: 1707-10
21. Qin JX, Shiota T, Lever HM, Asher CR, Popovic ZB, Greenberg NL, Agler DA, Drinko JK, Smedira NG, Tuzcu EM, Lytle BW, Thomas JD. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol. 2004; 93: 171-5.
22. Qin JX; Shiota T; Lever HM; Kapadia SR; Sitges M; Rubin DN; Bauer F; Greenberg NL; Agler DA; Drinko JK; Martin M; Tuzcu EM; Smedira NG; Lytle B; Thomas JD: Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J. Am. Coll. Cardiol. 2001; 38: 1994-2000.
23. Robbins RC, Stinson EB, Daily PO. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 1996; 111: 586-94
24. Schulte HD, Gramsch-Zabel H, Schwartzkopff B. Hypertrophische obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz. Med. Wochenschr. 1995; 125: 1940-9
25. Schulte HD, Bircks W, Lösse B, Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM), Z. Kardiol. 1987; 76 (supp. 3): 145-51
26. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-months follow-up in 25 patients. J. Am. Coll. Cardiol. 1998; 31: 252-8
27. Seggewiss H: Current status of alcohol septal ablation for patients with hypertrophic obstructive cardiomyopathy. Curr. Cardiol. Rep. 2001; 3: 160-6.
28. Spencer WH 3rd, Roberts R. Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: the need for a registry. Circulation. 2000; 102: 600-1
29. Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-14
30. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The managemant of hypertrophic cardiomyopathy. New. Engl. J. Med. 1997; 336: 775-85
31. Wigle DE, Rakowski H, Kimball BP, Williams WG: Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995; 92: 1680-92